Dr. Vincenzo Cirigliano has been appointed as Chief Technical Officer – CTO (Technical Director) of Veritas Intercontinental, European subsidiary of Veritas Genetics, “The Genome Company”. Dr. Cirigliano will also be responsible for the Veritas Intercontinental genetics laboratory in Spain, which will be located in Barcelona.

Dr. Cirigliano graduated in Biology from the University of Naples, trained in Genetics at the A.Cardarelli Hospital, before moving on to the National Research Council (IIGB), where he acquired extensive experience in molecular techniques and DNA sequencing for the diagnosis of genetic disorders. In addition, he participated in the sequencing of the Xq28 region for the Human Genome Project. He has been a member of the Board of Directors of the International Society for Prenatal Diagnosis (ISPD).

The Chief Technical Officer  of Veritas Intercontinental is also internationally recognized as a pioneer in the development and routine clinical introduction of innovative molecular tests in prenatal diagnosis, including the rapid diagnosis of aneuploidies, the introduction of microarrays and non-invasive prenatal diagnosis, using fetal nucleic acids in maternal plasma and fetal cells of the endocervical canal. After his stay at the Department of Obstetrics and Gynecology of the University College of London, in 2007 he obtained his Cum Laude doctorate in molecular and cellular biology with special mention from the Autonomous University of Barcelona, ​​where he participates in basic molecular cytogenetics research projects and clinic as an external teacher. Vincenzo Cirigliano is the author of many articles in important scientific journals, being a regular speaker at national and international conferences.

For the past 19 years, Dr. Cirigliano led the Molecular Genetics Department of Labco-Synlab, the largest network of clinical diagnostic laboratories in Europe.

About Veritas Intercontinental

Veritas Intercontinental is the international subsidiary of Veritas Genetics, The Genome Company, and operates in Europe, Latin America, Japan and the United Arab Emirates. Its mission is to promote Whole Genome Sequencing and offer people information that empowers them to maximize the quality and duration of their lives and that of their families, while changing the way in which the world perceives genetics.

Veritas was one of the first companies to offer sequencing and interpretation of the whole genome to consumers and their physicians leading the field of genetics, expanding the limits of science and technology and reducing the cost of the genome.

Veritas was founded in 2014 by leaders in genomics at Harvard Medical School and operates worldwide from its offices in the United States and Europe. The company has been recognized by MIT Technology Review as one of 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the most innovative healthcare companies in the world in 2018, and by CNBC as one of the companies Disruptor 50 companies in 2018 and 2019.